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Abstract: OBJECTIVES: We aimed to assess the predictive value of the SYNTAX score (SXscore)
for major adverse cardiac events in the all-comers population of the LEADERS (Limus Eluted from A
Durable versus ERodable Stent coating) trial. BACKGROUND: The SXscore has been shown to be
an effective predictor of clinical outcomes in patients with multivessel disease undergoing percutaneous
coronary intervention. METHODS: The SXscore was prospectively collected in 1,397 of the 1,707 patients
enrolled in the LEADERS trial (patients after surgical revascularization were excluded). Post hoc analysis
was performed by stratifying clinical outcomes at 1-year follow-up, according to 1 of 3 SXscore tertiles.
RESULTS: The 1,397 patients were divided into tertiles based on the SXscore in the following fashion:
SXscore<or=8 (SXlow) (n=464), SXscore>8 and <or=16 (SXmid) (n=472), and SXscore>16 (SXhigh)
(n=461). At 1-year follow-up, there was a significantly lower number of patients with major cardiac
event-free survival in the highest tertile of SXscore (SXlow=92.2%, SXmid=91.1%, and SXhigh=84.6%;
p<0.001). Death occurred in 1.5% of SXlow patients, 2.1% of SXmid patients, and 5.6% of SXhigh
patients (hazard ratio [HR]: 1.97, 95% confidence interval [CI]: 1.29 to 3.01; p=0.002). The myocardial
infarction rate tended to be higher in the SXhigh group. Target vessel revascularization was 11.3% in
the SXhigh group compared with 6.3% and 7.8% in the SXlow and SXmid groups, respectively (HR:
1.38, 95% CI: 1.1 to 1.75; p=0.006). Composite of cardiac death, myocardial infarction, and clinically
indicated target vessel revascularization was 7.8%, 8.9%, and 15.4% in the SXlow, SXmid, and SXhigh
groups, respectively (HR: 1.47, 95% CI: 1.19 to 1.81; p<0.001). CONCLUSIONS: The SXscore, when
applied to an all-comers patient population treated with drug-eluting stents, may allow prospective risk
stratification of patients undergoing percutaneous coronary intervention. (LEADERS Trial Limus Eluted
From A Durable Versus ERodable Stent Coating; NCT00389220). Copyright (c) 2010 American College
of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
DOI: 10.1016/j.jacc.2010.03.044
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-44635
Accepted Version
Originally published at:
Wykrzykowska, J J; Garg, S; Girasis, C; de Vries, T; Morel, M A; van Es, G A; Buszman, P; Linke,
A; Ischinger, T; Klauss, V; Corti, R; Eberli, F; Wijns, W; Morice, M C; di Mario, C; van Geuns, R J;
Juni, P; Windecker, S; Serruys, P W (2010). Value of the SYNTAX score for risk assessment in the
all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus
ERodable Stent coating) trial. Journal of the American College of Cardiology, 56(4):272-277. DOI:
10.1016/j.jacc.2010.03.044
2
1 
 
Value of the SYNTAX score (SX) for risk assessment in the “all-comers” population of the 
ra
Joanna J. W 1, Chrysafios Girasis MD1, Ton de 
Vr
Li
M
R
W
 
1. The Department of Interventional Cardiology Thoraxcenter, Erasmus MC, Rotterdam, NL, 
2. ardialysis B.V., Rotterdam, NL,  
3. Medical U
4. H
5. ausen, Munich, Germany 
6. enstadt), Munich, Germany  
7. itzerland 
8. 
9. I
10.
11. 
12.
 
7*
 
W
Fu
Corresponding author: 
Pr ys MD PhD 
Interventional Cardiology,  
Th
‘s Gravendijkwal 230 Bd 412 
30
Te
Fa
 
K value, biolimus-eluting stent, sirolimus-eluting stent, 
bi ularization, major adverse cardiac event 
ndomized multicenter LEADERS trial.  
ykrzykowska MD1, Scot Garg, MBChB, MRCP
ies MSc2, Marie-Angele Morel, BSc2, Gerrit-Anne van Es PhD2, Pawel Buszman, MD3, Axel 
nke, MD4, Thomas Ischinger, MD5, Volker Klauss, MD6, Roberto Corti, MD7, Franz Eberli, 
D PhD7*, William Wijns, MD8, Marie-Claude Morice MD9, Carlo di Mario, MD PhD10, 
obert Jan van Geuns MD PhD1, Peter Juni MD, PhD11, Stephan Windecker MD PhD12, Patrick 
. Serruys MD PhD1 
C
niversity of Silesia, Katowice, Poland 
erzzentrum Leipzig, Leipzig, Germany 
Department of Cardiology, Hospital Bogenh
Department of Cardiology, University Hospital Munich (Inn
rich, SwDepartment of Cardiology, University Hospital, Zu
Department of Cardiology, Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium 
nstitut Cardiovasculaire, Paris-Sud, Massy, France 
epartment of Cardiology, Royal Brompton Hospital, London, UK  D
CTU Bern, Bern University Hospital, Bern, Switzerland 
 Department of Cardiology, Bern University Hospital, Bern, Switzerland,  
Currently working at Triemlispital, Zurich, Switzerland 
ord count: 2,508 
nding: Biosensors Europe SA, Switzerland 
ofessor Patrick W. Serru
oraxcenter, Erasmus MC 
15CE Rotterdam, NL 
l: +31-10-4635260 
x: +31-10-4369154 
eywords: SYNTAX score, prognostic 
odegradable polymer, target vessel revasc
2 
 
Abbreviations : 
SXscore : SYNTAX score 
SXlow : SYNTAX score <8 
SXmid : SYNTAX score >8 and <16 
SX
SE
BE
TLR : target lesion revascularization 
TVR : target vessel revascularization 
M
M
H
RV
M iameter 
 
 
 
high : SYNTAX score >16 
S : sirolimus eluting stent 
S : biolimus eluting stent 
ACE : major adverse cardiac events 
I : myocardial infarction 
R : hazard ratio 
D : reference vessel diameter 
LD : minimal lumen d
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Abstract: 
Ba SYNTAX score (SXscore) has been shown to be an effective predictor of 
cli
in
Objective ing the predictive value of the SXscore for major adverse cardiac 
ev
M atients enrolled in the 
LEADERS trial (patients post-surgical revascularization were excluded). Post-hoc analysis was 
performed by stratifying clinical outcomes at 1 year follow-up, according to one of three 
SY
Results: 1,397 patients were divided into tertiles based on the SYNTAX score in the following 
fa SXmid ≤16 (n=472) and SXhigh >16 (n=461).  
A
ckground: The 
nical outcomes in patients with multivessel disease undergoing percutaneous coronary 
tervention (PCI).  
: We aimed at assess
ents in the “all-comers” population of the LEADERS trial. 
ethods: The SXscore was prospectively collected in 1,397 of the 1,707 p
NTAX score tertiles. 
shion: SXlow ≤8 (n=464), 8 <
t 1 year follow-up there was a significantly lower number of patients with MACE-free survival 
in the highest tertile of SX score (SXlow=92.2%, SXmid=91.1% and SXhigh=84.6%; p<0.001). 
Death occurred in 1.5% of patients with SYNTAX scores of <8, 2.1% of patients with 
in
3.
11
(H
cli
respectively (HR 1.47; CI 1.19-1.81; p<0.001). 
termediate scores of > 8 to 16 and 5.6% of patients with high scores of >16 (HR 1.97 CI 1.29-
01; p=0.002). Myocardial infarction rate tended to be higher in the SXhigh group. TVR was 
.3% in the SXhigh group versus 6.3% and 7.8% in the SXlow and SXmid groups, respectively 
R 1.38; CI 1.1-1.75; p=0.006). Composite of cardiac death, myocardial infarction and 
nically indicated TVR was 7.8%, 8.9% and 15.4% in the SXlow, SXmid and SXhigh, 
Kommentar [TDV1]: Because 
of 7.8% MACE 
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Conclusions: The SYNTAX score, when applied to an all-comers patient population treated with 
drug eluting stents, may allow for prospective risk stratification of patients undergoing PCI. 
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Introduction: 
The SYNTAX score (SXscore) is a comprehensive angiographic scoring system that is derived 
entirely from the coronary anatomy and lesion characteristics.(1-3) It was initially designed to 
quantify lesion complexity, however, it is also able to predict major adverse cardiac events 
(MACE) following percutaneous revascularization in patients with multivessel coronary artery 
disease(4-6) and/or left main disease.(7) More recent data indicates its ability to predict peri-
pr
intervent
ocedural myocardial infarction (MI) in patients undergoing elective percutaneous coronary 
ion (PCI). (8) In this sub-study of the LEADERS trial (Limus Eluted from A Durable 
versus ERodable Stent coating), where the SXscore was collected prospectively in 1,397 “all-
comer” patients, we assessed its prognostic value for MACE events at 1 year follow-up.  
Kommentar [C2]: Possibly 
anno ref here as well?include Capad
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Methods: 
Study population: LEADERS was a multicenter European non-inferiority trial comparing the 
sa
(B
du
ca
an
consent for participation in the trial. 
SX e baseline diagnostic angiogram, each coronary 
lesion producing ≥50% diameter stenosis in vessels ≥1.5 mm was scored separately and added 
to
al
ca
The N
infarction or previous PCI and CABG. Core lab analysts were blinded to all clinical data and 
therefore patients with occluded infarct related arteries were scored as occlusions of unknown 
du
re
St
of 
fety and efficacy of the BioMatrix™ Flex biolimus eluting stent with a biodegradable polymer 
ES) (Biosensors, Morges, Switzerland) to the Cypher® SelectTM sirolimus eluting stent with a 
rable polymer (SES) (Cordis, NJ, USA) in 1,707 ‘all-comers’ patients. Detailed study protocol 
n be found in the main manuscript.(9) The study complied with the Declaration of Helsinki 
d was approved by all institutional ethics committees. All patients provided written, informed 
score and angiographic analysis: From th
gether to provide the overall SXscore, which was calculated prospectively using the SXscore 
gorithm (described in full elsewhere).(1-3) All angiographic variables pertinent to SXscore 
lculation were computed by blinded core laboratory analysts (Cardialysis B.V., Rotterdam, 
etherlands). The SXscore is not currently validated in patients with acute myocardial 
ration in a similar manner to any chronically occluded artery. Those patients with in-stent 
stenosis lesions were scored in the same manner as if the lesion was a de novo lesion.  
udy endpoints: Definitions of all endpoints are provided elsewhere.(9) The primary endpoint 
this sub-study was MACE, defined as the composite of cardiac death, MI, and clinically-
indicated target vessel revascularization (TVR) within 9-months. Secondary endpoints were any 
target lesion revascularization (TLR) (both clinically and non-clinically indicated), any TVR, 
Kommentar [TDV3]: The 
anuscript  is for 12M, but primary 
dpoint was 9M fup 
m
en
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cardiac death, death from any cause, myocardial infarction, stent thrombosis (defined according 
to the Academic Research Council(10)), device success, and lesion success. 
The pre-specified principal outcome of the angiographic sub-study was in-stent percent diameter 
ste
lu
St iographic outcomes was 
perform
coronary angiography served to determine the SYNTAX score.(1,2) All randomized patients 
witho
ou
bi
Th
A
were two
presence of acute coronary syndrome as covariates. Testing for (linear) trend was done by using 
Generalized Linear Models with SX-class as a covariable for continuous variables and the 
Co
nosis. Secondary angiographic outcomes were in-segment percent diameter stenosis, minimal 
men diameter, late lumen loss, and binary restenosis.  
atistical analysis: A stratified post-hoc analysis of clinical and ang
ed according to the tertiles of the SYNTAX score.(4,5) Dedicated software and visual 
ut prior surgical revascularisation (1397/1707), were included in the analysis. Angiographic 
tcomes were analyzed using SAS v8 Proc Mixed for continuous and Proc Genmod for 
nominal outcomes, taking into account the within-patient correlation structure of these data. 
e Cox proportional hazards model was used to compare clinical outcomes between the groups. 
ll analyses were performed using SAS 8.02 by a dedicated statistician. All p-values and CIs 
-sided. Multivariate model included SXscore, diabetes, beta-blocker use, stent type and 
chran-Armitage test for trend in categorical data. 
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Results: 
SXscore and baseline characteristics: The SXscore was collected prospectively in 1,397 of the 
1,
m
707 patients (81.8%) enrolled in the LEADERS trial. The score ranged from 0 to 49, with a 
ean + SD of 13.5+8.7, and a median of 12 (inter-quartile range of 12; 7 to 19). In this post-hoc 
alysis, the SXscore tertiles were defined as: SXlow <an 8 (n=464), 8< SXmid ≤16 (n=472) and 
high >16 (n=461). Baseline clinical and angiographic characteristics of the patients are listed 
 table 1 and 2.  
ne year outcomes: S
SX
in
O Xscore significantly predicted the rate of MACE at 360 days (Table 3; 
Figures 1-4). There was a lower number of patients with MACE-free survival in the highest 
te
oc
SX
SX
7.8% in th
of cardiac death, myocardial infarction and clinically indicated TVR was 7.8%, 8.9% and 15.4% 
in the SXlow, SXmid and SXhigh, respectively (HR 1.47; CI 1.19-1.81; p<0.001). 
Multivariate model: In a multivariate model, SXscore remained a significant predictor of 
MACE and mortality. Patients in the SXhigh group had a 50% higher chance of the composite of 
ca
w
of BES tended to reduce the composite event rate by 26% (p=0.07).  
rtile of SYNTAX score (SXlow=92.2%, SXmid=91.1% and SXhigh=84.6%; p<0.001). Death 
curred in 1.5% of patients with SXlow, 2.1% of patients with SXmid and 5.6% of patients with 
high (HR 1.97 CI 1.29-3.01; p=0.002). The rate of MI tended to be higher in patients with 
high (HR MI 1.2 CI 0.9-1.61; p=0.22). TVR was 11.3% in the SXhigh group versus 6.3% and 
e SXlow and SXmid groups, respectively (HR 1.38; CI 1.1-1.75; p=0.006). Composite 
rdiac death, MI and clinically indicated TVR than patients in the SXmid group (p<0.001); 
hich was comparable to the 51% higher composite event rate among diabetics (p=0.022). Use 
9 
 
Stent thrombosis rates: The rate of definite stent thrombosis was 0.9%, 2.1% and 3.5% in the 
SXlow, SXmid and SXhigh, respectively
10 
 
Discussion: 
Complexity of disease and lesion characteristics are well recognized predictors of peri-
pr
co
fro
ocedural complications(8) and long-term mortality.(11-13) The SXscore was developed to 
mprehensively assess lesion characteristics and is based on the combination of classifications 
m the AHA/ACC, modified BARI classification, chronic total occlusion and bifurcation 
scores and Leaman classification.(1) It has previously been applied in both the SYNTAX trial 
and the ARTS-II study, which both demonstrated the good predictive value of the SXscore in 
patients with multivessel disease, with the highest tertile patients having significantly more 
MACE events during short(4,5) and long-term follow-up.(6) 
This study is the first to report the utility of the SXscore as a predictor of MACE, including 
cardiac death, in an “all-comers” population including patients with acute coronary syndromes. 
O
po
pow
Li
Th t it does not incorporate clinical patient characteristics. 
Patients with prior CABG have not been included as the SX score algorithm is only currently 
av ts with de novo disease. Modifications to the SXscore for risk stratification in 
pa
ac
verall this patient population had a much lower SYNTAX scores than the SYNTAX trial 
pulation, however, despite this the SYNTAX score still appears to have good discriminatory 
er for risk assessment.  
mitations: 
e limitation of the SXscore is tha
ailable for patien
tients post-CABG are currently being developed. The SXscore of patients who presented with 
ute MI, or had had previous PCI were included in this analysis, despite no previous validation 
Kommen
mention ca
registry her
tar [C4]: Need to 
padonno CUSTOMISE 
e. 
Kommentar [C5]: AUTAX 
probably needs a mention, but 
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in these patients. This study may suffer from limitations inherent to subgroup analysis (chance 
findings and under-powering).(14,15) (16) 
Conclusion: 
This study demonstrates that the prognostic value of the SYNTAX score is valid for all patients 
w
 
ith de novo coronary artery disease undergoing percutaneous revascularisation. 
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Table 1. Baseline clinical characteristics 
Ba
v
N=
e 8-16 
N=47
SX score >16 
61 
p-value on Trend 
 
seline clinical SX score <8 SX scor
ariables, n(%) 
464 2 N=4 (2-sided) 
Age >65 (%) 210 (45.3 224 (47.5 %  (51.8%) %) ) 239 0.048 
M 346 (7  (72.9ale  4,6%) 344 %) 340 (73.8%) 0.79 
D 93 (2  (24.8 4.1%) 
Current smoking 134 (28.9%) 121 (25.6%) 126 (27.3%) 0.61 
Hypertension 353 (76.1%) 353 (74.8%) 324 (70.3%) 0.048 
H 314 (67.7%) 66.5%) 1.8%) 
F 201 (4  (39.8 6.4%) 
R 3  (4.5% .1%) 
Pr 132 (2  (30.7 9.7%) 
Pr 179 (38 65 (35.0% 31.9%) 6 
PVD 26 (5.6%) 36 (7.6%) 31 (6.7%) 0.51 
Previous Stroke 13 (2.8%) 19 (4.0%) 16 (3.5%) 0.59 
C n: 
  
  
  
  I 
  Silent Ischaemia 
146 (31
127 (27
46 (9.9%) 
90 (1
55 (11.9%) 
 
54 (32.6%
18.9%
90 (19.1%) 
 (19.1
49 (10.4%) 
 
23.4%) 
19.1%) 
128 (27.8%) 
.0%) 
40 (8.7%) 
8 
2 
<0.0001 
0.12 
 
iabetes 0.0%) 117 %) 111 (2 0.15 
ypercholesterolemia 314 ( 285 (6 0.06 
amily history 3.3%) 188 %) 168 (3 0.034 
enal insufficiency 17 ( .7%) 21 ) 28 (6 0.09 
evious MI 8.5%) 145 %) 137 (2 0.69 
evious PCI .6%) 1 ) 147 ( 0.03
linical presentatio
Stable 
Unstable 
STEMI 
Non-STEM
 
.5%) 1
.4%) 89 (
9.4%) 90
) 108 (
) 88 (
%) 97 (21
 
0.00
0.00
0.54 
Kommentar [T
2 digits behind comma/
<0.06 
DV6]: I made it 
 3 digits If 
Kommentar [TDV7]: Data were 
LE, MALE was the 
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Table 2. Baseline angiographic characteristics: 
Angiographic variable SX score <8 SX score 8-16 SX score >16 p-value 
No. of diseased lesions per patient 
(based on SYNTAX ap 1.47+
 
plication) 0.66 2.37+1.00 3.45+1.44 <0.001 
N
(as defined by Corelab) 
o. of treated lesions per patient 1.2+0.46 1.47+0.7 1.69+0.86 <0.001 
R
le 1.22 1.61 
C
  
  
  
 
162 (34.9%)
140 (30.2%) 
216 (46.6%) 
 
2 (51.3%) 
144 (30.5%) 
209 (44.3%) 
 
64.2%) 
164 (35.6%) 
1 4 (37.7%) 
0.079 
007 
2-vessel disease 49 (10. .6% %) 
3-vessel dis 3 (0.7%)
Stent type 
  Biolimus 
  
 
229 (49.3%) 
235 (50.7
 
235 (49.8%) 
50.2%
 
239 (51.8%) 
2%) 
 
0.45 
N 1.47+
atio of diseased to treated 
sions 2.04 n/a 
oronary artery treated 
LAD 
LCX 
RCA 
 24 296 (
7
 
<0.001 
0.
6%) 102 (21 ) 138 (29.9 <0.001 
ease  13 (2.8%) 23 (5.0%) <0.001 
Sirolimus %) 237 ( ) 222 (48. 0.45 
umber of implanted stents 0.8 1.90+1.12 2.33+1.39 <0.001 
T th/patient (mm) 25.9+otal stent leng 16.5 34.2+21.7 42.9+26.2 
Chron 6 (1.3%)
M 23 (5.1% 0.3%) 9%) 
B 57 (12.3% 34.1% 9%) 
Use of 2 0 (17.2%) 23.9%) 
<0.001 
ic total occlusion  10 (2.1%) 19 (4.1%) 0.006 
oderate to severe calcification ) 96 (2 184 (39. <0.001 
ifurcation lesion ) 161 ( ) 184 (39. <0.001 
b3a 8  113 ( 154 (33.4%) <0.001 
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